pimitespib
Small moleculeexperimental
Clinical trial activity
4 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Apr 1, 2017 (NCT02965885)
Timeline
2010s
- Jan 1, 2017
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
- Biliary Tract Neoplasms · Phase 1
- Breast Neoplasms · Phase 1
- Carcinoma, Non-Small-Cell Lung · Phase 1
- Colorectal Neoplasms · Phase 1
- Endometrial Neoplasms · Phase 1
- Esophageal Neoplasms · Phase 1
- Gastrointestinal Stromal Tumors · Phase 1
- Head and Neck Neoplasms · Phase 1
- Neoplasms · Phase 1
- Pancreatic Neoplasms · Phase 1
- Retinoblastoma · Phase 1
- Sarcoma · Phase 1
- Sarcoma, Alveolar Soft Part · Phase 1
- Small Cell Lung Carcinoma · Phase 1
- Stomach Neoplasms · Phase 1
- Urinary Bladder Neoplasms · Phase 1
Mechanism of action
HSP90AB2P inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CCc1cc(C(N)=O)ccc1-n1nc(C(C)C)c2c(-n3cnc(-c4cnn(C)c4)c3)ccnc21- Mol. weight
- 454.54 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3661115 ↗
Also known as
- tas-116
- tas-116
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05655598 | Phase 1 | Mar 1, 2023 | Brown University |
| NCT05245968 | Phase 1 | Dec 1, 2021 | Otsuka |
| NCT04999761 | Phase 1 | Jun 1, 2021 | Otsuka |
| NCT02965885 | Phase 1 | Apr 1, 2017 | Otsuka |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Otsuka | For profit | 3 | 3 | 1 | 2017 |
| Brown University | Academic/Hospital | 1 | 1 | 1 | 2023 |
2 organizations
Page 1 / 1